S&K Therapeutics is a biopharmaceutical company founded in July 2020. S&K develops an innovative therapeutic approach based upon first-in-class inhibitors (small molecules) that modulate drug targets such as Toll-like receptors (TLRs), NLRP3, TNF-a, IL-23, IL-17, and IL-18. We employ cutting-edge science and technology (artificial intelligence, machine learning, and molecular dynamics simulation) to address some of society's most challenging healthcare issues.

Our mission is to develop breakthrough safe and effective therapies for unmet needs in autoimmune and inflammatory diseases such as systemic lupus erythematosus, psoriasis, heart failure/myocardial infarction, rheumatoid arthritis, Alzheimer's, and diabetes. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage drug discovery programs ready for out-licensing to partners and we have two commercially partnered programs with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development.

Currently, we are seeking discussions with potential out-licensing partners for our established Toll-like receptors (TLRs) inhibitors programs (S&K101 and S&K201).

TLR7 and TLR9, sequestered to the endosomal compartment of dendritic cells and macrophages, are primarily associated with the onset and development of inflammatory diseases, such as systemic lupus erythematosus, psoriasis and heart failure. We are introducing our two small-molecule (oral) lead drug candidates, S&K101 and S&K201 that showed significant inhibition of the TLR7 and TLR9 signaling and downregulated phosphorylation of the p65 subunit of NF-κB and MAPKs extracellular-signal–regulated kinase, p38 MAPK, and c-Jun N-terminal kinase. S&K101 were tested in lupus (lupus-prone MRL/lpr mice, NZB/NZW F1 mice) and psoriasis (IMQ and IL-23 mice model), and showed promising results by inhibiting the essential biomarkers such as dsDNA antibody, antinuclear antibodies (ANAs), albumin, IgG, IL-17, IL-23, and Ki67.

S&K201 is a potent and selective TLR9 inhibitor that blocks the synthetic single-stranded DNA (CpG ODNs) signaling of TLR9 such as CpG-B ODNs and CpG-C ODNs in cellular assay. The binding of HMGB1 to CpG ODNs significantly augmented cytokine production which is important in autoimmune and inflammatory diseases. S&K201 was tested in myocardial infarction (LAD model) and psoriasis, which showed greater potency in these disease models. The myocardial infarction disease associated indicators such as cross-sectional area, infarcted wall thickness/size, stroke work, stroke volume, heart rate, ejection rate, TNF, IL-6 and creatine kinase (CK-MB) were significantly overcome. These candidates had a great potential and may be efficacious in treating a variety of autoimmune and inflammatory diseases.

Therefore, we are seeking for companies with innovative technologies that can support hit finding or accelerate drug design across our early stage portfolio and licensing to take our assets through pre-clinical and clinical development.